BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announces that South Africa’s largest private insurance funder, Discovery Health and the key hospital groups, Life Healthcare, Netcare, Melomed and Busamed will provide coverage for the antibiotic-eluting bone graft substitutes, CERAMENT G and CERAMENT V.
Since BONESUPPORT received South African market authorization for its three CERAMENT products in late 2020, uptake has exclusively been in the public sector. Given coverage by these organisations, who together cover 4.6 million individuals, patient access is expected to increase.
“Access to CERAMENT G and CERAMENT V is set to improve the care of patients who develop bone infections in South Africa. They enable effective single-stage surgeries that support bone healing, prevent infection recurrence, and obviate the need for multiple surgeries. Our initial 18 months of experience with more than 40 patients have shown promising results,” said professor Nando Ferreira, Limb Reconstruction Surgeon at Tygerberg Hospital, Cape Town, and Professor of Orthopaedics at Stellenbosch University. Professor Nando Ferreira is an advisor to BONESUPPORT’s distributor in South Africa.
For more information contact:
BONESUPPORT Holding AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70
+46 (0) 708 76 87 87
BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 213 million in 2021. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.